Skip to main content

Table 6 Comparison of outcomes in patients between with and without acute and/or chronic GVHD

From: Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)

 

0-1 aGVHD% (95% CI) n = 386

2-4 aGVHD% (95% CI) n = 108

P

Non- cGVHD% (95% CI) n = 189

cGVHD% (95% CI) n = 277

P

NRM

14.3% (CI = 10.7%-19.3%)

32.0% (CI = 23.4%-43.9%)

0.000

15.7% (CI = 10.6%-23.2%)

12.1% (CI = 8.3%-17.6%)

0.194

RM

20.6% (CI = 16.2%-26.3%)

8.6% (CI = 4.2%-17.8%)

0.036

25.4% (CI = 19.0%-34.0%)

11.6% (CI = 7.6%-17.5%)

0.000

OS

69.4% (CI = 63.2%-75.6%)

62.7% (CI = 52.6%-72.9%)

0.009

62.0% (CI = 53.0%-71.1%)

80.0% (CI = 73.5%-86.4%)

0.000

LFS

68.0% (CI = 62.5%-73.5%)

61.0% (CI = 50.8%-71.1%)

0.047

61.8% (CI = 53.9%-69.7%)

77.4% (CI = 71.5%-83.3%)

0.000

  1. aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; NRM, non-relapse mortality; RM, relapse mortality; LFS, leukemia free survival; OS, overall survival.